Keynote 091: Adjuvant Pembrolizumab - OncTalk Lung 2023

(1:57)

KEYNOTE-091 and IMPOWER010: adjuvant chemotherapy for NSCLC

(4:48)

Upcoming NSCLC trials in 2022: CheckMate 816 \u0026 KEYNOTE-091

(2:1econd)

Immunotherapy for early-stage, resectable NSCLC: From clinical trial data to guidelines

(32:52)

Realizing the Promise of Perioperative Immunotherapy in Resectable NSCLC

(43:46)

INTerpath-002: pembrolizumab with a neoantigen therapy in completely resected NSCLC

(1:21)

Differences in treating lung cancer with adjuvant and neoadjuvant immunotherapy

(2:31)

Immunotherapy as combination and neoadjuvant therapies in NSCLC

(3:44)

Perioperative therapies in NSCLC

(3:16)

S1 Episode 4: Managing Lung Cancer With Neoadjuvant and Adjuvant Therapy

(24:30)

Paradigm Changes in the Perioperative Setting for Non-small Cell Lung Cancer - Karen Reckamp, MD

(22:53)

Keynote Presentation

(59:45)

IASLC Webinar: Perioperative Treatment w/Immune Checkpoint Inhibitors in Patients w/Resectable NSCLC

(1:1:6)

Moving immunotherapy to earlier lines in NSCLC

(2:22)

KEYNOTE Trial Data: Pembrolizumab’s Role in NSCLC

(8:19)

8 in 8: Update on Immunotherapy for Resectable Lung Cancer

(11:16)

The KEYNOTE-024 Precedent for Advanced-NSCLC Treatment

(3:31)

Perioperative Therapy in Early Stage NSCLC-Implications for Molecular Testing

(52:59)